Swallowed topical corticosteroids reduce the risk for long-lasting bolus impactions in eosinophilic esophagitis

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 69, Issue 9, 2014, Pages 1248-1254

  Kuchen, T ^a   Straumann, A ^b,c   Safroneeva, E ^d   Romero, Y ^e   Bussmann, C ^f   Vavricka, S ^a,b   Netzer, P ^b   Reinhard, A ^g   Portmann, S ^h   Schoepfer, A M ^g  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Swiss EoE Clinic ^*  (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e MAYO CLINIC   (United States)

^f Institute for Pathology   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h Kantonsspital Baden   (Switzerland)

Author keywords

budesonide; eosinophilic esophagitis; esophageal perforation; fluticasone; food impaction

Indexed keywords

BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; IMMUNOGLOBULIN E; ANDROSTANE DERIVATIVE; ANTIINFLAMMATORY AGENT; FLUTICASONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COHORT ANALYSIS; EOSINOPHIL COUNT; EOSINOPHILIC ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS DISEASE; ESOPHAGUS INJURY; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; FOOD IMPACTION; FOOD INTAKE; HISTOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; COMPLICATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CHILD; COHORT STUDIES; EOSINOPHILIC ESOPHAGITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84913599637     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12455     Document Type: Article

References (23)

1. Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011; 128: 3-20.
2. Hruz P, Straumann A, Bussmann C, Heer P, Simon HU, Zwahlen M, et al. Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County. Switzerland. J Allergy Clin Immunol 2011; 128: 1349-1350.
3. Prasad GA, Talley NJ, Romero Y, Arora AS, Kryzer LA, Smyrk TC, et al. Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol 2007; 102: 2627-2632.
4. Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU,. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003; 125: 1660-1669.
5. Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP, et al. Esophageal remodeling develops as a consequence of tissue-specific IL-5-induced eosinophilia. Gastroenterology 2008; 134: 204-214.
6. Aceves SS, Newbury RO, Dohil R, Bastian JF, Broide DH,. Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2007; 119: 206-212.
7. Kagalwalla AF, Akhtar N, Woodruff SA, Rea BA, Masterson JC, Mukkada V, et al. Eosinophilic esophagitis: epithelial mesenchymal transition contributes to esophageal remodeling and reverses with treatment. J Allergy Clin Immunol 2012; 129: 1387-1396.
8. Schoepfer AM, Safroneeva E, Bussmann C, Kuchen T, Portmann S, Simon HU, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation, in a time-dependent manner. Gastroenterology 2013; 145: 1230-1236.
9. Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I, et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012; 67: 477-490.
10. Straumann A, Bussmann C, Zuber M, Vannini S, Simon HU, Schoepfer A,. Eosinophilic esophagitis: analysis of food impaction and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol 2008; 6: 598-600.
11. Lucendo AJ, Friginal-Ruiz AB, Rodriguez B,. Boerhaave's syndrome as the primary manifestation of adult eosinophilic esophagitis. Two case reports and review of the literature. Dis Esophagus 2011; 24: E11-15.
12. Straumann A, Conus S, Degen L, Felder S, Kummer M, Engel H, et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010; 139: 1526-1537.
13. Abu-Sultaneh SM, Durst P, Maynard V, Elitsur Y,. Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis. Dig Dis Sci 2011; 56: 97-102.
14. Schroeder S, Fleischer DM, Masterson JC, Gelfand E, Furuta GT, Atkins D,. Successful treatment of eosinophilic esophagitis with ciclesonide. J Allergy Clin Immunol 2012; 129: 1419-1421.
15. Straumann A, Conus S, Degen L, Frei C, Bussmann C, Beglinger C, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011; 9: 400-409.
16. Aceves SS, Newbury RO, Chen D, Mueller J, Dohil R, Hoffman H, et al. Resolution of remodeling in eosinophilic esophagitis correlates with epithelial response to topical corticosteroids. Allergy 2010; 65: 109-116.
17. Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133: 1342-1363.
18. Hirano I, Moy N, Heckman MG, Thomas CS, Gonsalves N, Achem SR,. Endoscopic assessment of the esophageal features of eosinophilic esophagitis: validation of a novel classification and grading system. Gut 2013; 62: 489-495.
19. Schoepfer AM, Gonsalves N, Bussmann C, Conus S, Simon HU, Straumann A, et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety, and impact on the underlying inflammation. Am J Gastroenterol 2010; 105: 1062-1070.
20. Dellon ES, Sheikh A, Speck O, Woodward K, Whitlow AB, Hores JM, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012; 143: 321-324.
21. Dohil R, Newbury R, Fox L, Bastian J, Aceves S,. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010; 139: 418-429.
22. Nicodeme F, Hirano I, Chen J, Robinson K, Lin Z, Xiao Y, et al. Esophageal distensibility as a measure of disease severity in patients with Eosinophilic Esophagitis. Clin Gastroenterol Hepatol 2013; 11: 1101-1107.
23. Dellon ES, Gibbs WB, Rubinas TC, Fritchie KJ, Madanick RD, Woosley JT, et al. Esophageal dilation in eosinophilic esophagitis: safety and predictors of clinical response and complications. Gastrointest Endosc 2010; 71: 706-712.